TY - JOUR
T1 - Increased airway wall thickness in interstitial lung abnormalities and idiopathic pulmonary fibrosis
AU - Miller, Ezra R.
AU - Putman, Rachel K.
AU - Diaz, Alejandro A.
AU - Xu, Hanfei
AU - Estepar, Raul San Jose
AU - Araki, Tetsuro
AU - Nishino, Mizuki
AU - De Frias, Sergio Poli
AU - Hida, Tomoyuki
AU - Ross, James
AU - Coxson, Harvey
AU - Dupuis, Josee
AU - O'Connor, George T.
AU - Silverman, Edwin K.
AU - Rosas, Ivan O.
AU - Hatabu, Hiroto
AU - Washko, George
AU - Hunninghake, Gary M.
N1 - Funding Information:
Supported by National Institutes of Health (NIH) grant T32 HL007633 (E.R.M.); NIH grant K08 HL140087 (R.K.P.); NIH grants K01 HL118714 and R01 HL133137 (A.A.D.); NIH grants K25 HL104085 and R01 HL116473 (R.S.J.E.); NIH grant R01 CA203636 (M.N.); NIH grant K25 HL130637 (J.R.); NIH grant OT2 OD026553 (G.T.O’C.); NIH grants U01 HL089856, P01 HL114501, R01 HL113264, R01 HL133135, and R01 HL137927 (E.K.S.); NIH grant R01 HL130974, R01 HL129920, and U01 HL133232 (I.O.R.); NIH grant R01 HL122464 and R01 HL116473 (G.W.); and NIH grants R01 HL111024, R01 HL130974, and R01 HL135142 (G.M.H. and this work). The COPDGene (Genetic Epidemiology of COPD) study is supported by National Heart, Lung, and Blood Institute (NHLBI) grants U01 HL089897 and U01 HL089856. COPDGene (NCT00608764) is also supported by the COPD Foundation through contributions made to an industry advisory committee comprised of AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sunovion. The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study (NCT00292552; GSK code SCO104960) was sponsored by GlaxoSmithKline. This work was partially supported by the NHLBI’s Framingham Heart Study contract (N01-HC-25195). This work was supported by a generous gift from the family of David E. Herlihy to the Interstitial Diseases Group at Brigham and Women’s Hospital for the creation of the David E. Herlihy Data Registry and DNA Repository, which is also supported by NHLBI grant R01 HL130974.
Publisher Copyright:
©.
PY - 2019/4
Y1 - 2019/4
N2 - Rationale: There is increasing evidence that aberrant processes occurring in the airways may precede the development of idiopathic pulmonary fibrosis (IPF); however, there has been no prior confirmatory data derived from imaging studies. Objectives: To assess quantitative measures of airway wall thickness (AWT) in populations characterized for interstitial lung abnormalities (ILA) and for IPF. Methods: Computed tomographic imaging of the chest and measures of AWT were available for 6,073, 615, 1,167, and 38 participants from COPDGene (Genetic Epidemiology of COPD study), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study), and the Framingham Heart Study (FHS) and in patients with IPF from the Brigham and Women's Hospital Herlihy Registry, respectively. To evaluate these associations, we used multivariable linear regression to compare a standardized measure of AWT (the square root of AWT for airways with an internal perimeter of 10 mm [Pi10]) and characterizations of ILA and IPF by computed tomographic imaging of the chest. Results: In COPDGene, ECLIPSE, and FHS, research participants with ILA had increased measures of Pi10 compared with those without ILA. Patients with IPF had mean measures of Pi10 that were even greater than those noted in research participants with ILA. After adjustment for important covariates (e.g., age, sex, race, body mass index, smoking behavior, and chronic obstructive pulmonary disease severity when appropriate), research participants with ILA had increased measures of Pi10 compared with those without ILA (0.03 mm in COPDGene, 95% confidence interval [CI], 0.02-0.03; P, 0.001; 0.02 mm in ECLIPSE, 95% CI, 0.005-0.04; P = 0.01; 0.07 mm in FHS, 95% CI, 0.01-0.1; P = 0.01). Compared with COPDGene participants without ILA older than 60 years of age, patients with IPF were also noted to have increased measures of Pi10 (2.0 mm, 95% CI, 2.0-2.1; P, 0.001). Among research participants with ILA, increases in Pi10 were correlated with reductions in lung volumes in some but not all populations. Conclusions: These results demonstrate that measurable increases in AWT are consistently noted in research participants with ILA and in patients with IPF. These findings suggest that abnormalities of the airways may play a role in, or be correlated with, early pathogenesis of pulmonary fibrosis.
AB - Rationale: There is increasing evidence that aberrant processes occurring in the airways may precede the development of idiopathic pulmonary fibrosis (IPF); however, there has been no prior confirmatory data derived from imaging studies. Objectives: To assess quantitative measures of airway wall thickness (AWT) in populations characterized for interstitial lung abnormalities (ILA) and for IPF. Methods: Computed tomographic imaging of the chest and measures of AWT were available for 6,073, 615, 1,167, and 38 participants from COPDGene (Genetic Epidemiology of COPD study), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study), and the Framingham Heart Study (FHS) and in patients with IPF from the Brigham and Women's Hospital Herlihy Registry, respectively. To evaluate these associations, we used multivariable linear regression to compare a standardized measure of AWT (the square root of AWT for airways with an internal perimeter of 10 mm [Pi10]) and characterizations of ILA and IPF by computed tomographic imaging of the chest. Results: In COPDGene, ECLIPSE, and FHS, research participants with ILA had increased measures of Pi10 compared with those without ILA. Patients with IPF had mean measures of Pi10 that were even greater than those noted in research participants with ILA. After adjustment for important covariates (e.g., age, sex, race, body mass index, smoking behavior, and chronic obstructive pulmonary disease severity when appropriate), research participants with ILA had increased measures of Pi10 compared with those without ILA (0.03 mm in COPDGene, 95% confidence interval [CI], 0.02-0.03; P, 0.001; 0.02 mm in ECLIPSE, 95% CI, 0.005-0.04; P = 0.01; 0.07 mm in FHS, 95% CI, 0.01-0.1; P = 0.01). Compared with COPDGene participants without ILA older than 60 years of age, patients with IPF were also noted to have increased measures of Pi10 (2.0 mm, 95% CI, 2.0-2.1; P, 0.001). Among research participants with ILA, increases in Pi10 were correlated with reductions in lung volumes in some but not all populations. Conclusions: These results demonstrate that measurable increases in AWT are consistently noted in research participants with ILA and in patients with IPF. These findings suggest that abnormalities of the airways may play a role in, or be correlated with, early pathogenesis of pulmonary fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=85063732196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063732196&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.201806-424OC
DO - 10.1513/AnnalsATS.201806-424OC
M3 - Article
C2 - 30543456
AN - SCOPUS:85063732196
SN - 2325-6621
VL - 16
SP - 447
EP - 454
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 4
ER -